NK and NKT cells in liver injury and fibrosis

Clinical Immunology

Volumn 130, Issue 1, 2009, Pages 16-26

  Notas, George ^a,b   Kisseleva, Tatiana ^a   Brenner, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Cirrhosis; Fibrosis; Hepatic stellate cells; NK cells; NKT cells

Indexed keywords

GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 4; TOLL LIKE RECEPTOR;

ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; APOPTOSIS; AUTOIMMUNE DISEASE; CELL TYPE; CYTOKINE PRODUCTION; DOWN REGULATION; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INHIBITION KINETICS; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; NATURAL KILLER CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL; REVIEW; STELLATE CELL; VIRUS HEPATITIS;

ANIMALS; HEPATOVIRUS; HUMANS; KILLER CELLS, NATURAL; LIVER; LIVER CIRRHOSIS; MODELS, BIOLOGICAL; NATURAL KILLER T-CELLS;

EID: 57149093788     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.08.008     Document Type: Review

References (130)

1. Gao B., Jeong W.I., and Tian Z. Liver: an organ with predominant innate immunity. Hepatology 47 (2008) 729-736
2. Ahmad A., and Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J. Leukoc. Biol. 76 (2004) 743-759
3. Miller J.S., Verfaillie C., and McGlave P. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture. Blood 80 (1992) 2182-2187
4. Lian R.H., and Kumar V. Murine natural killer cell progenitors and their requirements for development. Semin. Immunol. 14 (2002) 453-460
5. Cooper M.A., Fehniger T.A., and Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol. 22 (2001) 633-640
6. Leibson P.J. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6 (1997) 655-661
7. Lanier L.L., Le A.M., Civin C.I., Loken M.R., and Phillips J.H. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136 (1986) 4480-4486
8. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., Carson W.E., and Caligiuri M.A. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97 (2001) 3146-3151
9. Moffett-King A. Natural killer cells and pregnancy. Nat. Rev. Immunol. 2 (2002) 656-663
10. Vivier E. What is natural in natural killer cells?. Immunol. Lett. 107 (2006) 1-7
11. Raulet D.H., and Vance R.E. Self-tolerance of natural killer cells. Nat. Rev. Immunol. 6 (2006) 520-531
12. Ljunggren H.G., and Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 162 (1985) 1745-1759
13. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., and Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999) 727-729
14. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 23 (2005) 225-274
15. Raulet D.H., Vance R.E., and McMahon C.W. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19 (2001) 291-330
16. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., Biassoni R., and Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19 (2001) 197-223
17. Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., and Caligiuri M.A. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100 (2002) 1935-1947
18. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5 (2005) 201-214
19. Karre K., Ljunggren H.G., Piontek G., and Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319 (1986) 675-678
20. Yu Y.Y., Kumar V., and Bennett M. Murine natural killer cells and marrow graft rejection. Annu. Rev. Immunol. 10 (1992) 189-213
21. Wallin R.P., Screpanti V., Michaelsson J., Grandien A., and Ljunggren H.G. Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur. J. Immunol. 33 (2003) 2727-2735
22. Oshimi Y., Oda S., Honda Y., Nagata S., and Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J. Immunol. 157 (1996) 2909-2915
23. Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., and Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195 (2002) 161-169
24. Degli-Esposti M.A., and Smyth M.J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5 (2005) 112-124
25. Martin-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., and Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 5 (2004) 1260-1265
26. Andoniou C.E., Andrews D.M., and Degli-Esposti M.A. Natural killer cells in viral infection: more than just killers. Immunol. Rev. 214 (2006) 239-250
27. Lodoen M.B., and Lanier L.L. Natural killer cells as an initial defense against pathogens. Curr. Opin. Immunol. 18 (2006) 391-398
28. Robertson M.J., and Ritz J. Biology and clinical relevance of human natural killer cells. Blood 76 (1990) 2421-2438
29. Vankayalapati R., Garg A., Porgador A., Griffith D.E., Klucar P., Safi H., Girard W.M., Cosman D., Spies T., and Barnes P.F. Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. J. Immunol. 175 (2005) 4611-4617
30. Bendelac A., Rivera M.N., Park S.H., and Roark J.H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15 (1997) 535-562
31. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., and Van Kaer L. NKT cells: what's in a name?. Nat. Rev. Immunol. 4 (2004) 231-237
32. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.R., Koezuka Y., and Kronenberg M. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192 (2000) 741-754
33. Geissmann F., Cameron T.O., Sidobre S., Manlongat N., Kronenberg M., Briskin M.J., Dustin M.L., and Littman D.R. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 3 (2005) e113
34. Swain M.G. Hepatic NKT cells: friend or foe?. Clin. Sci. (Lond.) 114 (2008) 457-466
35. Emoto M., Miyamoto M., Namba K., Schmits R., Van Rooijen N., Kita E., and Kaufmann S.H. Participation of leukocyte function-associated antigen-1 and NK cells in the homing of thymic CD8+ NKT cells to the liver. Eur. J. Immunol. 30 (2000) 3049-3056
36. Morita M., Motoki K., Akimoto K., Natori T., Sakai T., Sawa E., Yamaji K., Koezuka Y., Kobayashi E., and Fukushima H. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J. Med. Chem. 38 (1995) 2176-2187
37. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., and Taniguchi M. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
38. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y.P., Yamashita T., Teneberg S., Wang D., Proia R.L., Levery S.B., Savage P.B., Teyton L., and Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789
39. Mattner J., Debord K.L., Ismail N., Goff R.D., Cantu III C., Zhou D., Saint-Mezard P., Wang V., Gao Y., Yin N., Hoebe K., Schneewind O., Walker D., Beutler B., Teyton L., Savage P.B., and Bendelac A. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 (2005) 525-529
40. Bendelac A., Savage P.B., and Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 25 (2007) 297-336
41. Metelitsa L.S., Naidenko O.V., Kant A., Wu H.W., Loza M.J., Perussia B., Kronenberg M., and Seeger R.C. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167 (2001) 3114-3122
42. Yoshimoto T., and Paul W.E. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179 (1994) 1285-1295
43. Oki S., Chiba A., Yamamura T., and Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 113 (2004) 1631-1640
44. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23 (2005) 877-900
45. Carnaud C., Lee D., Donnars O., Park S.H., Beavis A., Koezuka Y., and Bendelac A. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163 (1999) 4647-4650
46. Eberl G., and MacDonald H.R. Rapid death and regeneration of NKT cells in anti-CD3epsilon- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 9 (1998) 345-353
47. Uldrich A.P., Crowe N.Y., Kyparissoudis K., Pellicci D.G., Zhan Y., Lew A.M., Bouillet P., Strasser A., Smyth M.J., and Godfrey D.I. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contractionand hyporesponsiveness to further antigenic challenge. J. Immunol. 175 (2005) 3092-3101
48. Tsuyuki S., Yamauchi A., Nakamura H., Nakamura Y., Kinoshita K., Gomi T., Kawai Y., Hirose T., Furuke K., Ikai I., Ohmori K., Yamaoka Y., and Inamoto T. N-acetylcysteine improves cytotoxic activity of cirrhotic rat liver-associated mononuclear cells. Int. Immunol. 10 (1998) 1501-1508
49. Golden-Mason L., Kelly A.M., Doherty D.G., Traynor O., McEntee G., Kelly J., Hegarty J.E., and O'Farrelly C. Hepatic interleukin 15 (IL-15) expression: implications for local NK/NKT cell homeostasis and development. Clin. Exp. Immunol. 138 (2004) 94-101
50. Vanderkerken K., Bouwens L., Van Rooijen N., Van den Berg K., Baekeland M., and Wisse E. The role of Kupffer cells in the differentiation process of hepatic natural killer cells. Hepatology 22 (1995) 283-290
51. Schmieg J., Yang G., Franck R.W., Van Rooijen N., and Tsuji M. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1127-1132
52. Werner-Wasik M., von Muenchhausen W., Nolan J.P., and Cohen S.A. Endogenous interferon alpha/beta produced by murine Kupffer cells augments liver-associated natural killing activity. Cancer. Immunol. Immunother. 28 (1989) 107-115
53. Tu Z., Bozorgzadeh A., Pierce R.H., Kurtis J., Crispe I.N., and Orloff M.S. TLR-dependent cross talk between human Kupffer cells and NK cells. J. Exp. Med. 205 (2008) 233-244
54. Dong Z., Wei H., Sun R., Hu Z., Gao B., and Tian Z. Involvement of natural killer cells in PolyI:C-induced liver injury. J. Hepatol. 41 (2004) 966-973
55. Chen Y., Sun R., Jiang W., Wei H., and Tian Z. Liver-specific HBsAg transgenic mice are over-sensitive to Poly(I:C)-induced liver injury in NK cell- and IFN-gamma-dependent manner. J. Hepatol. 47 (2007) 183-190
56. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., and Schwabe R.F. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 13 (2007) 1324-1332
57. Biburger M., and Tiegs G. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J. Immunol. 175 (2005) 1540-1550
58. Muhlen K.A., Schumann J., Wittke F., Stenger S., Van Rooijen N., Van Kaer L., and Tiegs G. NK cells, but not NKT cells, are involved in Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity in mice. J. Immunol. 172 (2004) 3034-3041
59. Dobashi H., Seki S., Habu Y., Ohkawa T., Takeshita S., Hiraide H., and Sekine I. Activation of mouse liver natural killer cells and NK1.1(+) T cells by bacterial superantigen-primed Kupffer cells. Hepatology 30 (1999) 430-436
60. Kaneko Y., Harada M., Kawano T., Yamashita M., Shibata Y., Gejyo F., Nakayama T., and Taniguchi M. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J. Exp. Med. 191 (2000) 105-114
61. Takeda K., Hayakawa Y., Van Kaer L., Matsuda H., Yagita H., and Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5498-5503
62. Kawamura H., Aswad F., Minagawa M., Govindarajan S., and Dennert G. P2X7 receptors regulate NKT cells in autoimmune hepatitis. J. Immunol. 176 (2006) 2152-2160
63. Bayon L.G., Izquierdo M.A., Sirovich I., van Rooijen N., Beelen R.H., and Meijer S. Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver. Hepatology 23 (1996) 1224-1231
64. Griffini P., Smorenburg S.M., Vogels I.M., Tigchelaar W., and Van Noorden C.J. Kupffer cells and pit cells are not effective in the defense against experimentally induced colon carcinoma metastasis in rat liver. Clin. Exp. Metastasis. 14 (1996) 367-380
65. Roh M.S., Kahky M.P., Oyedeji C., Klostergaard J., Wang L., Curley S.A., and Lotzova E. Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases. Clin. Exp. Metastasis. 10 (1992) 317-327
66. Shiratori Y., Nakata R., Okano K., Komatsu Y., Shiina S., Kawase T., Sugimoto T., Omata M., and Tanaka M. Inhibition of hepatic metastasis of colon carcinoma by asialo GM1-positive cells in the liver. Hepatology 16 (1992) 469-478
67. Rushfeldt C., Sveinbjornsson B., Seljelid R., and Smedsrod B. Early events of hepatic metastasis formation in mice: role of Kupffer and NK-cells in natural and interferon-gamma-stimulated defense. J. Surg. Res. 82 (1999) 209-215
68. Malter M., Suss R., and Fischer H. Natural cytotoxic cells from rat liver and spleen kill human glioma cells. J. Cancer. Res. Clin. Oncol. 113 (1987) 498-501
69. Smyth M.J., Crowe N.Y., and Godfrey D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13 (2001) 459-463
70. Ledesma F., Echevarria S., Casafont F., Lozano J.L., and Pons-Romero F. Natural killer cell activity in alcoholic cirrhosis: influence of nutrition. Eur. J. Clin. Nutr. 44 (1990) 733-740
71. Morizane T., Watanabe T., Tsuchimoto K., and Tsuchiya M. Impaired T cell function and decreased natural killer activity in patients with liver cirrhosis and their significance in the development of hepatocellular carcinoma. Gastroenterol. Jpn. 15 (1980) 226-232
72. Nakamura T., Morizane T., Watanabe T., Tsuchimoto K., Inagaki Y., Kumagai N., and Tsuchiya M. Decreased natural killer activity in patients with liver cirrhosis. Int. J. Cancer 32 (1983) 573-575
73. Charpentier B., Franco D., Paci L., Charra M., Martin B., Vuitton D., and Fries D. Deficient natural killer cell activity in alcoholic cirrhosis. Clin. Exp. Immunol. 58 (1984) 107-115
74. Chuang W.L., Liu H.W., Chang W.Y., Chen S.C., Hsieh M.Y., and Wang L.Y. Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage. Dig. Dis. Sci. 36 (1991) 299-302
75. Par A., Szekeres-Bartho J., Pacsa S., and Javor T. Effect of cianidanol on natural killer cell activity in patients with chronic B virus hepatitis. Int. J. Clin. Pharmacol. Res. 7 (1987) 301-306
76. Actis G.C., Ponzetto A., D'Urso N., Saracco G., Crepaldi T., Bellone G., Catucci L.M., Zarcone D., and Verme G. Chronic active hepatitis B. Interferon-activated natural killer-like cells against a hepatoma cell line transfected with the hepatitis B virus nucleic acid. Liver 11 (1991) 106-113
77. Duan X.Z., Wang M., Li H.W., Zhuang H., Xu D., and Wang F.S. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J. Clin. Immunol. 24 (2004) 637-646
78. Hirai N., Kato Y., Kobayashi K., and Hattori N. Natural killer (NK) cell activity and its in vitro response to interferon-alpha(Le) in chronic liver diseases and hepatocellular carcinoma. Liver 6 (1986) 212-220
79. Wada T., Arima T., and Nagashima H. Natural killer activity in patients with chronic hepatitis treated with OK432, interferon, adenine arabinoside and glycyrrhizin. Gastroenterol. Jpn. 22 (1987) 312-321
80. Ono K., Yamanaga Y., Yamamoto K., Koga S.I., Nishimura J., and Nawata H. Natural killing activities in chronic liver diseases and hepatocellular carcinoma. J. Clin. Immunol. 16 (1996) 41-45
81. Chen Y., Wei H., Sun R., and Tian Z. Impaired function of hepatic natural killer cells from murine chronic HBsAg carriers. Int. Immunopharmacol. 5 (2005) 1839-1852
82. Chen Y., Wei H., Sun R., Dong Z., Zhang J., and Tian Z. Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells. Hepatology 46 (2007) 706-715
83. Vilarinho S., Ogasawara K., Nishimura S., Lanier L.L., and Baron J.L. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 18187-18192
84. Webster G.J., Reignat S., Maini M.K., Whalley S.A., Ogg G.S., King A., Brown D., Amlot P.L., Williams R., Vergani D., Dusheiko G.M., and Bertoletti A. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32 (2000) 1117-1124
85. Sprengers D., van der Molen R.G., Kusters J.G., Hansen B., Niesters H.G., Schalm S.W., and Janssen H.L. Different composition of intrahepatic lymphocytes in the immune-tolerance and immune-clearance phase of chronic hepatitis B. J. Med. Virol. 78 (2006) 561-568
86. Mosnier J.F., Pham B.N., Walker F., Dubois S., Degos F., Erlinger S., and Degott C. Relationship between composition of lymphoid cell infiltrates in the liver and replication status in chronic hepatitis B: an immunohistochemical study. Am. J. Clin. Pathol. 106 (1996) 625-633
87. Ando K., Moriyama T., Guidotti L.G., Wirth S., Schreiber R.D., Schlicht H.J., Huang S.N., and Chisari F.V. Mechanisms of class I restricted immunopathologyA transgenic mouse model of fulminant hepatitis. J. Exp. Med. 178 (1993) 1541-1554
88. Dunn C., Brunetto M., Reynolds G., Christophides T., Kennedy P.T., Lampertico P., Das A., Lopes A.R., Borrow P., Williams K., Humphreys E., Afford S., Adams D.H., Bertoletti A., and Maini M.K. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 204 (2007) 667-680
89. Yoo Y.K., Gavaler J.B., Chen K., Whiteside T.L., and van Thiel D.H. The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals. Clin. Exp. Immunol. 82 (1990) 338-343
90. Li Y., Zhang T., Ho C., Orange J.S., Douglas S.D., and Ho W.Z. Natural killer cells inhibit hepatitis C virus expression. J. Leukoc. Biol. 76 (2004) 1171-1179
91. Kawarabayashi N., Seki S., Hatsuse K., Ohkawa T., Koike Y., Aihara T., Habu Y., Nakagawa R., Ami K., Hiraide H., and Mochizuki H. Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 32 (2000) 962-969
92. Morishima C., Paschal D.M., Wang C.C., Yoshihara C.S., Wood B.L., Yeo A.E., Emerson S.S., Shuhart M.C., and Gretch D.R. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 43 (2006) 573-580
93. Long E.O. Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17 (1999) 875-904
94. Diefenbach A., and Raulet D.H. Strategies for target cell recognition by natural killer cells. Immunol. Rev. 181 (2001) 170-184
95. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., Cheng J., Goedert J.J., Vlahov D., Hilgartner M., Cox S., Little A.M., Alexander G.J., Cramp M.E., O'Brien S.J., Rosenberg W.M., Thomas D.L., and Carrington M. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 (2004) 872-874
96. Nattermann J., Feldmann G., Ahlenstiel G., Langhans B., Sauerbruch T., and Spengler U. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 55 (2006) 869-877
97. Paladino N., Flores A.C., Marcos C.Y., Fainboim H., Theiler G., Arruvito L., Williams F., Middleton D., and Fainboim L. Increased frequencies of activating natural killer receptors are associated with liver injury in individuals who do not eliminate hepatitis C virus. Tissue Antigens 69 (Suppl. 1) 1 (2007) 109-111
98. Kakimi K., Guidotti L.G., Koezuka Y., and Chisari F.V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192 (2000) 921-930
99. Baron J.L., Gardiner L., Nishimura S., Shinkai K., Locksley R., and Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 16 (2002) 583-594
100. de Lalla C., Galli G., Aldrighetti L., Romeo R., Mariani M., Monno A., Nuti S., Colombo M., Callea F., Porcelli S.A., Panina-Bordignon P., Abrignani S., Casorati G., and Dellabona P. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J. Immunol. 173 (2004) 1417-1425
101. Nuti S., Rosa D., Valiante N.M., Saletti G., Caratozzolo M., Dellabona P., Barnaba V., and Abrignani S. Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis. Eur. J. Immunol. 28 (1998) 3448-3455
102. Durante-Mangoni E., Wang R., Shaulov A., He Q., Nasser I., Afdhal N., Koziel M.J., and Exley M.A. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J. Immunol. 173 (2004) 2159-2166
103. Laso F.J., Lapena P., Madruga J.I., San Miguel J.F., Orfao A., Iglesias M.C., and Alvarez-Mon M. Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake. Alcohol. Clin. Exp. Res. 21 (1997) 1226-1231
104. Muller C., Wolf H., Gottlicher J., and Eibl M.M. Phenotypic analysis of lymphocytes involved in major histocompatibility complex unrestricted cellular cytotoxicity in patients with alcoholic cirrhosis. Int. Arch. Allergy Appl. Immunol. 91 (1990) 329-334
105. James S.P., and Jones E.A. Abnormal natural killer cytotoxicity in primary biliary cirrhosis: evidence for a functional deficiency of cytolytic effector cells. Gastroenterology 89 (1985) 165-171
106. Nishigaki Y., Ohnishi H., Moriwaki H., and Muto Y. Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. Dig. Dis. Sci. 41 (1996) 1487-1493
107. Matheson D.S., Green B.J., and Minuk G.Y. Natural killer-cell activity and the response to interferons alpha, beta, and gamma in patients with primary biliary cirrhosis. J. Allergy Clin. Immunol. 84 (1989) 214-218
108. Bjorkland A., Festin R., Mendel-Hartvig I., Nyberg A., Loof L., and Totterman T.H. Blood and liver-infiltrating lymphocytes in primary biliary cirrhosis: increase in activated T and natural killer cells and recruitment of primed memory T cells. Hepatology 13 (1991) 1106-1111
109. Chuang Y.H., Lian Z.X., Tsuneyama K., Chiang B.L., Ansari A.A., Coppel R.L., and Eric Gershwin M. Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J. Autoimmun. 26 (2006) 232-240
110. Hashimoto E., Lindor K.D., Homburger H.A., Dickson E.R., Czaja A.J., Wiesner R.H., and Ludwig J. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo. Clin. Proc. 68 (1993) 1049-1055
111. Bo X., Broome U., Remberger M., and Sumitran-Holgersson S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 49 (2001) 131-341
112. Karlsen T.H., Boberg K.M., Olsson M., Sun J.Y., Senitzer D., Bergquist A., Schrumpf E., Thorsby E., and Lie B.A. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J. Hepatol. 46 (2007) 899-906
113. Melum E., Karlsen T.H., Schrumpf E., Bergquist A., Thorsby E., Boberg K.M., and Lie B.A. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 47 (2008) 90-96
114. Kita H., Naidenko O.V., Kronenberg M., Ansari A.A., Rogers P., He X.S., Koning F., Mikayama T., Van De Water J., Coppel R.L., Kaplan M., and Gershwin M.E. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123 (2002) 1031-1043
115. Harada K., Isse K., Tsuneyama K., Ohta H., and Nakanuma Y. Accumulating CD57 + CD3 + natural killer T cells are related to intrahepatic bile duct lesions in primary biliary cirrhosis. Liver Int. 23 (2003) 94-100
116. Tsuneyama K., Yasoshima M., Harada K., Hiramatsu K., Gershwin M.E., and Nakanuma Y. Increased CD1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis. Hepatology 28 (1998) 620-623
117. Chuang Y.H., Lian Z.X., Yang G.X., Shu S.A., Moritoki Y., Ridgway W.M., Ansari A.A., Kronenberg M., Flavell R.A., Gao B., and Gershwin M.E. Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 47 (2008) 571-580
118. Dunk A.A., Novick D., and Thomas H.C. Natural killer cell activity in hepatocellular carcinoma. In vitro and in vivo responses to interferon. Scand. J. Gastroenterol. 22 (1987) 1245-1250
119. Saibara T., Onishi S., Sakaeda H., and Yamamoto Y. Defective function of lymphokine-activated killer cells and natural killer cells in patients with hepatocellular carcinoma. Hepatology 9 (1989) 471-476
120. Nakajima T., Mizushima N., and Kanai K. Relationship between natural killer activity and development of hepatocellular carcinoma in patients with cirrhosis of the liver. Jpn. J. Clin. Oncol. 17 (1987) 327-332
121. Chuang W.L., Liu H.W., and Chang W.Y. Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer 65 (1990) 926-930
122. Shirachi M., Sata M., Miyajima I., Tanaka M., and Tanikawa K. Liver-associated natural killer activity in cirrhotic rats. Microbiol. Immunol. 42 (1998) 117-124
123. Asseman C., Pancre V., Quatennens B., and Auriault C. Schistosoma mansoni-infected mice show augmented hepatic fibrosis and selective inhibition of liver cytokine production after treatment with anti-NK1.1 antibodies. Immunol. Lett. 54 (1996) 11-120
124. Radaeva S., Sun R., Jaruga B., Nguyen V.T., Tian Z., and Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130 (2006) 435-452
125. Radaeva S., Wang L., Radaev S., Jeong W.I., Park O., and Gao B. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am. J. Physiol. Gastrointest. Liver Physiol. 293 (2007) G809-G816
126. Melhem A., Muhanna N., Bishara A., Alvarez C.E., Ilan Y., Bishara T., Horani A., Nassar M., Friedman S.L., and Safadi R. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol. 45 (2006) 60-71
127. Horani A., Muhanna N., Pappo O., Melhem A., Alvarez C.E., Doron S., Wehbi W., Dimitrios K., Friedman S.L., and Safadi R. Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 292 (2007) G628-G638
128. Jeong W.I., Park O., Radaeva S., and Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation andstimulating NK cell cytotoxicity. Hepatology 44 (2006) 1441-1451
129. Jeong W.I., Park O., and Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 134 (2008) 248-258
130. Safadi R., Zigmond E., Pappo O., Shalev Z., and Ilan Y. Amelioration of hepatic fibrosis via beta-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution. Int. Immunol. 19 (2007) 1021-1029